This week, longtime healthcare veterans Amy Abernethy and Brad Hirsch teamed up to launch Highlander Health — a Dallas-based startup focused on accelerating clinical evidence generation.
Verily’s recent moves have signaled the company’s interest in supporting decentralized clinical trials and real-world studies. Now the life sciences subsidiary of Alphabet is bolstering its capabilities in these areas with the acquisition of startup SignalPath.
Employees who enjoy their benefits are more inclined to stay with their company. A 2025 Marsh McLennan Agency report said 73% of employees would remain if plan options were better.
Gottlieb, who is expected to step down in about a month, leaves behind a unique legacy and will likely be difficult to replace.
Oncologist Amy Abernethy, who currently serves as Flatiron's chief medical officer, chief scientific officer and senior vice president of oncology, will join the agency in the next few months.
Dr. Amy Abernethy, a medical oncologist from Duke University School of Medicine who has championed clinical informatics and working with patients to develop more personalized cancer care, has joined Flatiron Health.